Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.

•We characterize cMET gene and protein expression in Chinese gastric cancer patients.•We identify correlations between cMET gene, protein expression and response.•Volitinib shows potent activity in cMET-dysregulated cell lines and PDX models.•Our data highlight the potential for volitinib in cMET-driven gastric cancers.